Alx Oncology Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
34.9%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.65next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Expected Release of Safety Data for ALX2004 Phase 1 Trial | 31 Dec 2026 |
| Expected Topline Data Readout for ASPEN-09-Breast Phase 2 Trial (80 patients) | 30 Jun 2027 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Investments Quarterly169.1MTarget: Sufficient to fund planned operations through the first half of 2028
Quarterly Research and Development (R&D) Expenses Quarterly13.6M
Quarterly Net Loss (GAAP) Quarterly-17.9M
Watch Items
- ASPEN-09-Breast Phase 2 clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapyTrigger: Topline data readout for 80 patientsAction: Evaluate clinical efficacy (objective response rate and duration of response) stratified by CD47 expression levels to validate the CD47-selection biomarker hypothesis.
- ALX2004 Phase 1 clinical trial dose-escalation in patients with EGFR-expressing solid tumorsTrigger: Initial safety and tolerability data readoutAction: Review safety profile, dose-limiting toxicities, and determine the recommended Phase 2 dose (RP2D) for the EGFR-targeted antibody-drug conjugate.
- Dose optimization of evorpacept combined with SARCLISA (isatuximab) and dexamethasone in relapsed or refractory multiple myelomaTrigger: Completion of dose optimization cohortAction: Assess safety and efficacy signals to determine registrational path or potential development partnerships.
Research as of 19 Jun 2026